Savara Inc.
$5.61
▼
-0.36%
2026-04-21 09:41:00
www.savarapharma.com
NMS: SVRA
Explore Savara Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$1.15 B
Current Price
$5.61
52W High / Low
$7 / $1.89
Stock P/E
—
Book Value
$0.8
Dividend Yield
—
ROCE
-52.68%
ROE
-63.45%
Face Value
—
EPS
$-0.53
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
70
Beta
0.31
Debt / Equity
14.73
Current Ratio
11.85
Quick Ratio
11.85
Forward P/E
-17.69
Price / Sales
—
Enterprise Value
$1.23 B
EV / EBITDA
-10
EV / Revenue
—
Rating
Strong Buy
Target Price
$10.81
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Revelation Biosciences, Inc. | $1.16 | — | $4.32 M | — | -94.64% | -1.31% | $43.48 / $0.99 | $5.59 |
| 2. | HCW Biologics Inc. | $0.41 | — | $2.94 M | — | -4764.31% | -897.37% | $17.8 / $0.25 | $-0.8 |
| 3. | Adial Pharmaceuticals, Inc. | $1.63 | — | $2.33 M | — | -147.82% | -1.71% | $687.5 / $1.54 | $4.75 |
| 4. | Sutro Biopharma, Inc. | $34.58 | — | $572.9 M | — | -106.34% | 435.02% | $34.58 / $5.23 | $-15.43 |
| 5. | AC Immune SA | $2.98 | — | $303.29 M | — | -115.62% | -89.65% | $4 / $1.45 | $0.56 |
| 6. | Septerna, Inc. | $26.86 | — | $1.17 B | — | -15.87% | -12.19% | $32.63 / $5.73 | $8.52 |
| 7. | vTv Therapeutics Inc. | $37.75 | — | $157.78 M | — | -39.41% | -78.94% | $44 / $14 | $5.19 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M | 0 M | — |
| Operating Profit | -33.42 M | -30.25 M | -31.44 M | -27.65 M | -31.17 M | — |
| Net Profit | -32.24 M | -29.56 M | -30.4 M | -26.64 M | -29.04 M | — |
| EPS in Rs | -0.16 | -0.14 | -0.15 | -0.13 | -0.14 | -0.11 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 0 M | 0 M | 0 M | 0 M |
| Operating Profit | -122.76 M | -102.4 M | -59.21 M | -38.04 M |
| Net Profit | -118.84 M | -95.88 M | -54.7 M | -38.15 M |
| EPS in Rs | -0.58 | -0.47 | -0.27 | -0.19 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 253.44 M | 212.88 M | 177.56 M | 139.78 M |
| Total Liabilities | 50.3 M | 41.43 M | 37.19 M | 32 M |
| Equity | 203.13 M | 171.45 M | 140.37 M | 107.78 M |
| Current Assets | 241.62 M | 202.13 M | 165.95 M | 128.95 M |
| Current Liabilities | 20.4 M | 14.72 M | 10.6 M | 5.87 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -101.04 M | -89.09 M | -51.06 M | -34.55 M |
| Investing CF | -18.44 M | -39.94 M | -57.12 M | 52.65 M |
| Financing CF | 137.81 M | 117.58 M | 82.78 M | 0.09 M |
| Free CF | -101.06 M | -89.11 M | -51.36 M | -34.56 M |
| Capex | -0.02 M | -0.03 M | -0.3 M | -0.01 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | -75.29% | -43.38% | — | — |
| Profit Margin % | — | — | — | — |
| Operating Margin % | — | — | — | — |
| Gross Margin % | — | — | — | — |
| EBITDA Margin % | — | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.